Extended Data Table 2 Dose delays, dose reductions and dose omissions per drug in each treatment cycle per patient in the per protocol population (n = 20)

From: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial